Tennessee § 71-5-166 Annual review of medications and forms of treatment for sickle cell disease, and services for enrollees with diagnosis of sickle cell disease, that are eligible for coverage under medical assistance program

Tennessee Statutes

§ 71-5-166 — Annual review of medications and forms of treatment for sickle cell disease, and services for enrollees with diagnosis of sickle cell disease, that are eligible for coverage under medical assistance program

Tennessee § 71-5-166

Title71

This text of Tennessee § 71-5-166 (Annual review of medications and forms of treatment for sickle cell disease, and services for enrollees with diagnosis of sickle cell disease, that are eligible for coverage under medical assistance program) is published on Counsel Stack Legal Research, covering Tennessee primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Tenn. Code Ann. § 71-5-166 (2026).

Text

(a)This section is known and may be cited as "Terrence's Law." (b) The bureau of TennCare shall conduct an annual review of all medications and forms of treatment for sickle cell disease, and services for enrollees with a diagnosis of sickle cell disease, that are eligible for coverage under the medical assistance program. The purpose of the annual review is to determine if the available covered medications, treatments, and services are adequate to meet the needs of enrollees with a diagnosis of sickle cell disease, and whether the bureau should seek to add additional medications, treatments, or services.

(c)When conducting the annual review required by this section, the bureau of TennCare shall solicit and consider input from the general public, with specific emphasis on attempting to r

Free access — add to your briefcase to read the full text and ask questions with AI

(a) This section is known and may be cited as "Terrence's Law." (b) The bureau of TennCare shall conduct an annual review of all medications and forms of treatment for sickle cell disease, and services for enrollees with a diagnosis of sickle cell disease, that are eligible for coverage under the medical assistance program. The purpose of the annual review is to determine if the available covered medications, treatments, and services are adequate to meet the needs of enrollees with a diagnosis of sickle cell disease, and whether the bureau should seek to add additional medications, treatments, or services. (c) When conducting the annual review required by this section, the bureau of TennCare shall solicit and consider input from the general public, with specific emphasis on attempting to receive input from persons or groups with knowledge and experience in the area of sickle cell disease treatment. (d) On or before January 15, 2022, and on or before January 15 each year thereafter, the bureau of TennCare shall submit a report to the chief clerks of the senate and the house of representatives for distribution to the appropriate subject matter committees, and to the legislative librarian, that details the bureau's findings from the annual review required by this section, as well as any recommendations to the general assembly based upon those findings. The bureau shall publish the annual report required by this subsection (d) to its website in a manner accessible by the general public.